TY  - GEN
AU  - Friedberg,Jonathan W
AU  - Mahadevan,Daruka
AU  - Cebula,Erin
AU  - Persky,Daniel
AU  - Lossos,Izidore
AU  - Agarwal,Amit B
AU  - Jung,Jungah
AU  - Burack,Richard
AU  - Zhou,Xiaofei
AU  - Leonard,E Jane
AU  - Fingert,Howard
AU  - Danaee,Hadi
AU  - Bernstein,Steven H
TI  - Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas
SN  - 1527-7755
PY  - 2014///0228
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Aurora Kinase A
KW  - antagonists & inhibitors
KW  - Azepines
KW  - Burkitt Lymphoma
KW  - drug therapy
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Lymphoma, Follicular
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Lymphoma, Mantle-Cell
KW  - Lymphoma, T-Cell
KW  - Male
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - methods
KW  - Protein Kinase Inhibitors
KW  - Pyrimidines
KW  - Recurrence
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1200/JCO.2012.46.8793
ER  -